Romu Corbau Email

CSO . GenEdit

South San Francisco, CA

Location

r******@genedit.com

Primary Email

Current Roles

Employees:
57
Revenue:
$8.8M
About
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications. In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, current CRISPR delivery methods rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. A non-viral CRISPR/Cas9 delivery method is needed. In addition, low efficiency levels achieved make it impossible to target certain diseases. GenEdit's novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.
GenEdit Address
681 Gateway Blvd
South San Francisco, CA
United States
GenEdit Email

Past Companies

GenEditCSO
FreelineCSO
FreelineSVP Research

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.